Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Net Margin (2016 - 2025)

Historic Net Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 7753.42%.

  • Celldex Therapeutics' Net Margin fell 63186000.0% to 7753.42% in Q2 2025 from the same period last year, while for Sep 2025 it was 8636.31%, marking a year-over-year decrease of 70918300.0%. This contributed to the annual value of 2249.29% for FY2024, which is 1945300.0% down from last year.
  • Latest data reveals that Celldex Therapeutics reported Net Margin of 7753.42% as of Q2 2025, which was down 63186000.0% from 7741.01% recorded in Q1 2025.
  • Celldex Therapeutics' Net Margin's 5-year high stood at 384.28% during Q2 2021, with a 5-year trough of 22088.34% in Q2 2022.
  • For the 5-year period, Celldex Therapeutics' Net Margin averaged around 7057.4%, with its median value being 5020.42% (2021).
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -217040600bps in 2022, then soared by 132897600bps in 2025.
  • Over the past 5 years, Celldex Therapeutics' Net Margin (Quarter) stood at 6032.34% in 2021, then skyrocketed by 73bps to 1642.1% in 2022, then surged by 36bps to 1048.32% in 2023, then crashed by -282bps to 4008.51% in 2024, then crashed by -93bps to 7753.42% in 2025.
  • Its Net Margin stands at 7753.42% for Q2 2025, versus 7741.01% for Q1 2025 and 4008.51% for Q4 2024.